
MK-3475-789
NCT03515837
JCP045
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)
Status:
Closed to Accrual

III
Phase

2nd+
Line of Therapy

Advanced / Metastatic
Disease Stage

Biomarker(s)
EGFR
Investigational
Product
Pembrolizumab (MK-3475)
Anti-PD1 antibody (i.v.)
Treatment Arms
o Experimental: Pembro+Pemetrexed+Chemo
o Active Comparator: Placebo+Pemetrexed+Chemo